An open label, randomized study for the comparison of effectiveness between glucagon-like peptide-1 (GLP-1) analogue in people with type 2 diabetes treated bolus first or basal first insulin therapy

Not Applicable

• Conditions: Type 2 diabetes

• Registration Number: JPRN-UMIN000010354
• Lead Sponsor: Department of Disease Control and Homeostasis,kanazawa University Graduate School of Medical Science.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-03-29
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1.Hypersensitivity to components of liraglutide and exenatide 2.None Type 2 diabetes 3.Medical history and/or complication of diabetic ketoacidosis 4.Medical history and/or complication of severe hypoglycemia 5.Severe infection, around surgery or severe trauma 6.Patients who received the administration of DPP-4 inhibitors or GLP-1 analogue within 4 weeks 7.Treatment with glucocorticoid 8.Uncontrolled Hypertension(systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg) 9.Proliferative retinopathy or maculopathy 10.History of malignancy 11.Severe health problems not suitable for the study 12.Pregnant or lactating woman 13.Cases that Physicians deem inappropriate as the target of the test

Study & Design

• Study Type: Interventional
• Study Design: Not specified